Fungicidas evaluados para combatir el añublo polvoriento en pimiento

The effectiveness of benomyl, chlorothalonil, copper hydroxide, dinocap, sulfur and triadimefon for the control of the fungus Leveillula taurica, causal agent of the powdery mildew of peppers (Capsicum annuum), was evaluated under field conditions. Results from two experiments indicate that weekly applications of benomyl and triadimefon reduced disease incidence and increased pepper yield. In the first experiment, plots treated with triadimefon (0.35 L/ha) and benomyl (0.55 kg/ha) produced 20.2 and 17.2 kg fruit/plot, respectively, whereas the nontreated plots yielded 13,9 kg/plot. A similar trend but with higher yields was obtained in the second experiment. Treatments with triadimefon (0.70 L/ha) and benomyl (0.55 kg/ha) produced 41.0 and 41.3 kg of fruit/plot, respectively, as compared with the control treatments which yielded 29.0 kg/plot.Se evaluó bajo condiciones de campo la eficacia de los fungicidas benomyl, hidróxido de cobre, dinocap, azufre y triadimefon para combatir el añublo polvoriento del pimiento (Leveillula taurica). Los resultados obtenidos demuestran que las aplicaciones semanales de los fungicidas benomyl y triadimefon reprimieron el patógeno, aminoraron la severidad de infección y aumentaron significativamente el rendimiento. En la primera prueba se obtuvieron rendimientos de 20.2 y 17.2 kg./parcela con aplicaciones de triadimefon (0.35 L./ha.) y benomyl (0.55 kg./ha.), respectivamente, mientras que en las parcelas sin tratar el rendimiento obtenido fue de 13.9 kg. En la segunda prueba, aun cuando los resultados fueron similares a los anteriores, se obtuvieron mejores rendimientos. Se obtuvieron rendimientos de 41.0 y 41.3 kg. en parcelas tratadas con triadimefon (0.70 L./ha.) y benomyl (0.55 kg./ha.); en las parcelas sin tratar se obtuvo un rendimiento de 29.0 kg./ha

AN EVALUATION OF 10 CUCUMBER (CUCUMIS SATIVA L.) CULTIVARS IN SOUTHERN PUERTO RICO

AN EVALUATION OF 10 CUCUMBER (CUCUMIS SATIVA L.) CULTIVARS IN SOUTHERN PUERTO RIC

Religión y diversidad sexual: Tensiones y disyuntivas en narraciones biográficas

Este artículo pretende explicitar las tensiones y disyuntivas que emergen en la articulación de dos dimensiones que, a nuestro entender, resultan ineludibles al momento de pensar modos de subjetivación contemporáneos: la religión y la sexualidad. Por un lado los movimientos feministas y LGBTI han posicionado la sexualidad en el centro de los debates contemporáneos sobre identidad, subjetividad y sociedad y, por otro, las religiones han resistido al pretendido declive que las teorías secularistas de la modernidad habían diagnosticado. A fin de comprender las complejas articulaciones entre pertenencias religiosas e identidad sexual se ponen en diálogo dos experiencias biográficas para explicitar las tensiones y disyuntivas entre visibilidad e invisibilidad desde esta doble vertiente: ser parte activa de una comunidad religiosa (católica en un caso y evangélica en el otro) y, al mismo tiempo, experimentar/vivenciar una identidad sexual disidente

Extreme Saharan dust event over the southern Iberian Peninsula in september 2007: active and passive remote sensing from surface and satellite

This study investigates aerosol optical properties during the extreme Saharan dust event detected from 3 to 7 September 2007 over Granada, southern Iberian Peninsula, with both active and passive remote sensing instrumentation from surface and satellite. The intensity of the event was visualized on the aerosol optical depth series obtained by the sun-photometer Cimel CE 318-4 operated at Granada in the framework of AERONET from August 2004 until December 2008 (level 2 data). A combination of large aerosol optical depth (0.86–1.50) at 500 nm, and reduced Angström exponent (0.1–0.25) in the range 440–870 nm, was detected on 6 September during daytime. This Saharan dust event also affected other Iberian Peninsula stations included in AERONET (El Arenosillo and Évora stations), and it was monitored by MODIS instrument on board Aqua satellite. Vertically resolved measurements were performed by a ground-based Raman Lidar and by CALIPSO satellite. During the most intense stage, on 6 September, maximum aerosol backscatter values were a factor of 8 higher than other maxima during this Saharan dust event. Values up to 1.5×10−2 km−1 sr−1 at 355 and 532 nm were detected in the layer with the greatest aerosol load between 3–4 km a.s.l., although aerosol particles were also detected up to 5.5 km a.s.l. In this stage of the event, dust particles at these altitudes showed a backscatter-related Angström exponent between –0.44 and 0.53 for the two spectral intervals considered. The results from different measurements (active/passive and ground-based/satellite) reveal the importance of performing multi-instrumental measurements to properly characterize the contribution of different aerosol types from different sources during extreme events. The atmospheric stabilization effect of the aerosol particles has been characterized by computing the solar heating rates using SBDART code.This work is supported by the Spanish Ministry of Education project CGL2007-66477-C02-01 and CSD2007-00067, by Andalusian Regional Government projects P06-RNM-01503 and P08-RNM-3568, and by the EARLINETASOS project (EU Coordination Action, contract No. 025991 (RICA))

Contribución de las políticas públicas a la realización efectiva de los derechos de la mujer

En el presente estudio se parte de que la protección efectiva e integral de los derechos de las mujeres constituye una de las tareas inacabadas de mayor alcance en las sociedades contemporáneas. En él se analizan las políticas públicas que desde un enfoque de la igualdad y no discriminación tienen influencia en las esferas pública y privada; tratándose todo ello conforme a los postulados de la Ley Orgánica española 3/2007, de 22 de marzo, para la igualdad efectiva de mujeres y hombres. Por último, se aportan veintiséis recomendaciones y propuestas para hacer que los derechos de las mujeres sean tomados en serioIn this study the premise is the effective and comprehensive protection of women's rights as one of the most important pending duties of modern society. Public policies are analysed from the perspective of equality and non‐discrimination in public and private fields, all of which are considered in accordance with the Fundamental Act 3/2007 of 22nd March, for the effective equality between women and men. Lastly, twenty‐six recommendations are proposed in order that women's rights may be taken seriously

Contribución de las políticas públicas a la realización efectiva de los derechos de la mujer

En el presente estudio se parte de que la protección efectiva e integral de los derechos de las mujeres constituye una de las tareas inacabadas de mayor alcance en las sociedades contemporáneas. En él se analizan las políticas públicas que desde un enfoque de la igualdad y no discriminación tienen influencia en las esferas pública y privada; tratándose todo ello conforme a los postulados de la Ley Orgánica española 3/2007, de 22 de marzo, para la igualdad efectiva de mujeres y hombres. Por último, se aportan veintiséis recomendaciones y propuestas para hacer que los derechos de las mujeres sean tomados en serioIn this study the premise is the effective and comprehensive protection of women's rights as one of the most important pending duties of modern society. Public policies are analysed from the perspective of equality and non‐discrimination in public and private fields, all of which are considered in accordance with the Fundamental Act 3/2007 of 22nd March, for the effective equality between women and men. Lastly, twenty‐six recommendations are proposed in order that women's rights may be taken seriously

Contribución de las políticas públicas a la realización efectiva de los derechos de la mujer

En el presente estudio se parte de que la protección efectiva e integral de los derechos de las mujeres constituye una de las tareas inacabadas de mayor alcance en las sociedades contemporáneas. En él se analizan las políticas públicas que desde un enfoque de la igualdad y no discriminación tienen influencia en las esferas pública y privada; tratándose todo ello conforme a los postulados de la Ley Orgánica española 3/2007, de 22 de marzo, para la igualdad efectiva de mujeres y hombres. Por último, se aportan veintiséis recomendaciones y propuestas para hacer que los derechos de las mujeres sean tomados en serio

Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization

Plitidepsin is a marine-derived cyclic-peptide that inhibits SARS-CoV-2 replication at low nanomolar concentrations by the targeting of host protein eEF1A (eukaryotic translation-elongation-factor-1A). We evaluated a model of intervention with plitidepsin in hospitalized COVID-19 adult patients where three doses were assessed (1.5, 2 and 2.5 mg/day for 3 days, as a 90-minute intravenous infusion) in 45 patients (15 per dose-cohort). Treatment was well tolerated, with only two Grade 3 treatment-related adverse events observed (hypersensitivity and diarrhea). The discharge rates by Days 8 and 15 were 56.8% and 81.8%, respectively, with data sustaining dose-effect. A mean 4.2 log10 viral load reduction was attained by Day 15. Improvement in inflammation markers was also noted in a seemingly dose-dependent manner. These results suggest that plitidepsin impacts the outcome of patients with COVID-19.This study has been funded by Pharmamar, S.A. (Madrid, Spain). This work was supported by grants from the Government of Spain (PIE_INTRAMURAL_ LINEA 1 - 202020E079; PIE_INTRAMURAL_CSIC-202020E043). The research of CBIG consortium (constituted by IRTA-CReSA, BSC, & IrsiCaixa) is supported by Grifols pharmaceutical. We also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). N.I.U. has non-restrictive funding from PharmaMar to study the antiviral effect of Plitidepsin. N.J.K. was funded by grants from the National Institutes of Health (P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694, and P01AI063302); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between UCSF, UCB, and GSK (#133122P); by the Roddenberry Foundation, and gifts from QCRG philanthropic donors. This work was supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement #HR0011-19-2-0020. The views, opinions, and/or findings contained in this material are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. This research was partly funded by CRIP (Center for Research for Influenza Pathogenesis), a NIAID supported Center of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), by DARPA grant HR0011-19-2-0020, by supplements to NIAID grants U19AI142733, U19AI135972 and DoD grant W81XWH-20-1-0270, and by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384)), and anonymous donors to AG-S. S.Y. received funding from a Swiss National Foundation (SNF) Early Postdoc Mobility fellowship (P2GEP3_184202).N

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19

Plitidepsin, a marine-derived cyclic-peptide, inhibits SARS-CoV-2 replication at nanomolar concentrations by targeting the host protein eukaryotic translation elongation factor 1A. Here, we show that plitidepsin distributes preferentially to lung over plasma, with similar potency against across several SARS-CoV-2 variants in preclinical studies. Simultaneously, in this randomized, parallel, open-label, proof-of-concept study (NCT04382066) conducted in 10 Spanish hospitals between May and November 2020, 46 adult hospitalized patients with confirmed SARS-CoV-2 infection received either 1.5 mg (n = 15), 2.0 mg (n = 16), or 2.5 mg (n = 15) plitidepsin once daily for 3 d. The primary objective was safety; viral load kinetics, mortality, need for increased respiratory support, and dose selection were secondary end points. One patient withdrew consent before starting procedures; 45 initiated treatment; one withdrew because of hypersensitivity. Two Grade 3 treatment-related adverse events were observed (hypersensitivity and diarrhea). Treatment-related adverse events affecting more than 5% of patients were nausea (42.2%), vomiting (15.6%), and diarrhea (6.7%). Mean viral load reductions from baseline were 1.35, 2.35, 3.25, and 3.85 log10 at days 4, 7, 15, and 31. Nonmechanical invasive ventilation was required in 8 of 44 evaluable patients (16.0%); six patients required intensive care support (13.6%), and three patients (6.7%) died (COVID-19-related). Plitidepsin has a favorable safety profile in patients with COVID-19.This work was supported by grants from the Government of Spain (PIE_INTRAMURAL_ LINEA 1 - 202020E079; PIE_INTRAMURAL_CSIC-202020E043). The research of CBIG consortium (constituted by IRTA-CReSA, BSC, & IrsiCaixa) is supported by Grifols pharmaceutical. We also acknowledge the crowdfunding initiative #Yomecorono (https://www.yomecorono.com). N Izquierdo-Useros has nonrestrictive funding from PharmaMar to study the antiviral effect of Plitidepsin. NJ Krogan was funded by grants from the National Institutes of Health (P50AI150476, U19AI135990, U19AI135972, R01AI143292, R01AI120694, and P01AI063302); by the Excellence in Research Award (ERA) from the Laboratory for Genomics Research (LGR), a collaboration between the University of California, San Francisco (UCSF), University of California, Berkley (UCB), and GlaxoSmithKline (GSK) (#133122P); by the Roddenberry Foundation, and gifts from QCRG philanthropic donors. This work was supported by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement #HR0011-19-2-0020. The views, opinions, and/or findings contained in this material are those of the authors and should not be interpreted as representing the official views or policies of the Department of Defense or the U.S. Government. This research was partly funded by Center for Research for Influenza Pathogenesis and Transmission (CRIPT), a National Institute of Allergy and Infectious Diseases (NIAID) supported Center of Excellence for Influenza Research and Response (CEIRS, contract # 75N93021C00014), by DARPA grant HR0011-19-2-0020, by supplements to NIAID grants U19AI142733, U19AI135972, and DoD grant W81XWH-20-1-0270, and by the generous support of the JPB Foundation, the Open Philanthropy Project (research grant 2020-215611 (5384)), and anonymous donors to A García-Sastre. S Yildiz received funding from a Swiss National Foundation Early Postdoc Mobility fellowship (P2GEP3_184202).Peer reviewe

Medidas y cálculos de dosis de radiación en pacientes sometidos a procedimientos de Tomografía Computarizada

Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Ciencias, Departamento de Física de Materiales. Fecha de lectura: 14-05-200